JNJ

230.64

+1.43%↑

ISRG

496

-1.52%↓

ABT

109.39

+0.15%↑

RDY

13.59

+1.42%↑

NEOG

10.23

+0.2%↑

JNJ

230.64

+1.43%↑

ISRG

496

-1.52%↓

ABT

109.39

+0.15%↑

RDY

13.59

+1.42%↑

NEOG

10.23

+0.2%↑

JNJ

230.64

+1.43%↑

ISRG

496

-1.52%↓

ABT

109.39

+0.15%↑

RDY

13.59

+1.42%↑

NEOG

10.23

+0.2%↑

JNJ

230.64

+1.43%↑

ISRG

496

-1.52%↓

ABT

109.39

+0.15%↑

RDY

13.59

+1.42%↑

NEOG

10.23

+0.2%↑

JNJ

230.64

+1.43%↑

ISRG

496

-1.52%↓

ABT

109.39

+0.15%↑

RDY

13.59

+1.42%↑

NEOG

10.23

+0.2%↑

Search

Inmode Ltd

Slēgts

SektorsVeselības aprūpe

16.62 5.79

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

15.71

Max

16.66

Galvenie mērījumi

By Trading Economics

Ienākumi

-4.9M

22M

Pārdošana

-2.4M

93M

P/E

Sektora vidējais

7.418

90.422

EPS

0.38

Peļņas marža

23.467

Darbinieki

599

EBITDA

-5.4M

26M

Rekomendācijas

By TipRanks

Rekomendācijas

Neitrāls

Prognoze 12 mēnešiem

+10.31% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2026. g. 10. febr.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

119M

1B

Iepriekšējā atvēršanas cena

10.83

Iepriekšējā slēgšanas cena

16.62

Tehniskais rādītājs

By Trading Central

Pārliecība

Bearish Evidence

Inmode Ltd Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 2. febr. 23:52 UTC

Iegādes, apvienošanās, pārņemšana

Elliott Management Doesn't Plan to Tender Its Shares at the Current Terms

2026. g. 2. febr. 23:52 UTC

Iegādes, apvienošanās, pārņemšana

Elliott Management: Toyota Fudosan Revised Tender Offer for Toyota Industries 'Very Significantly Undervalues' Company

2026. g. 2. febr. 23:48 UTC

Tirgus saruna

Nikkei May Rise on Signs of U.S. Economic Strength -- Market Talk

2026. g. 2. febr. 23:38 UTC

Tirgus saruna

Gold Rises on Likely Technical Recovery, Dip-Buying Interest -- Market Talk

2026. g. 2. febr. 23:28 UTC

Tirgus saruna

SpaceX, xAI Deal Further Consolidates Musk's Businesses -- Market Talk

2026. g. 2. febr. 23:23 UTC

Peļņas

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- 2nd Update

2026. g. 2. febr. 22:57 UTC

Peļņas

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2026. g. 2. febr. 22:22 UTC

Iegādes, apvienošanās, pārņemšana

What the Blockbuster SpaceX--xAI Merger Can Mean for Tesla Stock -- Barrons.com

2026. g. 2. febr. 22:08 UTC

Tirgus saruna

Australian Inflation Woes Rooted In Excess Govt Spending -- Market Talk

2026. g. 2. febr. 21:51 UTC

Peļņas

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2026. g. 2. febr. 21:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 2. febr. 21:49 UTC

Peļņas

Disney's Streaming Profit Surges as CEO Decision Approaches -- 5th Update

2026. g. 2. febr. 21:39 UTC

Peļņas

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2026. g. 2. febr. 21:36 UTC

Peļņas

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- Update

2026. g. 2. febr. 21:34 UTC

Peļņas

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2026. g. 2. febr. 21:28 UTC

Iegādes, apvienošanās, pārņemšana

What a SpaceX--xAI Merger Could Mean for Tesla Stock -- Barrons.com

2026. g. 2. febr. 21:23 UTC

Peļņas

BYD, Chinese EV Stock Plunge On Weak Data. What That Means for Tesla Stock. -- Barrons.com

2026. g. 2. febr. 21:19 UTC

Peļņas

Palantir Technologies: U.S. Commercial Business Growing at 'Astonishing' Rate, Generating $507 Million Last Quarter, 137% Increase Over the Same Period the Year Before >PLTR

2026. g. 2. febr. 21:17 UTC

Peļņas

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- WSJ

2026. g. 2. febr. 21:17 UTC

Peļņas

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2026. g. 2. febr. 21:10 UTC

Peļņas

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2026. g. 2. febr. 21:08 UTC

Peļņas

Palantir Technologies: Rule of 40 Score Is Now 127% >PLTR

2026. g. 2. febr. 21:07 UTC

Peļņas

Palantir Technologies: Sees 2026 U.S. Comml Rev in Excess of $3.144B, Representing Growth Rate of at Least 115% >PLTR

2026. g. 2. febr. 21:05 UTC

Peļņas

Palantir Technologies 4Q Net $608.7M >PLTR

2026. g. 2. febr. 21:05 UTC

Peļņas

Palantir Technologies 4Q Rev $1.41B >PLTR

2026. g. 2. febr. 21:05 UTC

Peļņas

Palantir Technologies Sees 1Q Rev $1.53B-$1.54B >PLTR

2026. g. 2. febr. 21:05 UTC

Peļņas

Palantir Technologies Sees FY Rev $7.18B-$7.2B >PLTR

2026. g. 2. febr. 21:05 UTC

Peļņas

Palantir Technologies 4Q Adj EPS 25c >PLTR

2026. g. 2. febr. 21:05 UTC

Peļņas

Palantir Technologies 4Q EPS 24c >PLTR

2026. g. 2. febr. 20:40 UTC

Tirgus saruna

Treasury Yields, Dollar Rise Amid Signs of Resilient U.S. Economy -- Market Talk

Salīdzinājums

Cenas izmaiņa

Inmode Ltd Prognoze

Cenas mērķis

By TipRanks

10.31% augšup

Prognoze 12 mēnešiem

Vidējais 17.33 USD  10.31%

Augstākais 21 USD

Zemākais 15 USD

Pamatojoties uz 6 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Inmode Ltd — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Neitrāls

6 ratings

1

Pirkt

5

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

14.1 / 14.44Atbalsts un pretestība

Īstermiņā

Bearish Evidence

Vidējā termiņā

Strong Bearish Evidence

Ilgtermiņā

Bearish Evidence

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Inmode Ltd

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was incorporated in 2008 and is headquartered in Yokne'am, Israel.
help-icon Live chat